78 related articles for article (PubMed ID: 10924700)
21. Studies of the biogenic amine transporters. VIII: identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding.
Rothman RB; Dersch CM; Carroll FI; Ananthan S
Synapse; 2002 Mar; 43(4):268-74. PubMed ID: 11835522
[TBL] [Abstract][Full Text] [Related]
22. Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression.
Lin Z; Itokawa M; Uhl GR
FASEB J; 2000 Apr; 14(5):715-28. PubMed ID: 10744628
[TBL] [Abstract][Full Text] [Related]
23. Protein tyrosine kinase inhibitors alter human dopamine transporter activity in Xenopus oocytes.
Doolen S; Zahniser NR
J Pharmacol Exp Ther; 2001 Mar; 296(3):931-8. PubMed ID: 11181926
[TBL] [Abstract][Full Text] [Related]
24. Dopamine transporter transmembrane domain polar mutants: DeltaG and DeltaDeltaG values implicate regions important for transporter functions.
Itokawa M; Lin Z; Cai NS; Wu C; Kitayama S; Wang JB; Uhl GR
Mol Pharmacol; 2000 Jun; 57(6):1093-103. PubMed ID: 10825379
[TBL] [Abstract][Full Text] [Related]
25. The region of dopamine transporter encompassing the 3rd transmembrane domain is crucial for function.
Lee SH; Kang SS; Son H; Lee YS
Biochem Biophys Res Commun; 1998 May; 246(2):347-52. PubMed ID: 9610361
[TBL] [Abstract][Full Text] [Related]
26. Delineation of an endogenous zinc-binding site in the human dopamine transporter.
Norregaard L; Frederiksen D; Nielsen EO; Gether U
EMBO J; 1998 Aug; 17(15):4266-73. PubMed ID: 9687495
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type.
Eshleman AJ; Carmolli M; Cumbay M; Martens CR; Neve KA; Janowsky A
J Pharmacol Exp Ther; 1999 May; 289(2):877-85. PubMed ID: 10215666
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter.
Pifl C; Drobny H; Reither H; Hornykiewicz O; Singer EA
Mol Pharmacol; 1995 Feb; 47(2):368-73. PubMed ID: 7870046
[TBL] [Abstract][Full Text] [Related]
29. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate.
Chen R; Han DD; Gu HH
J Neurochem; 2005 Jul; 94(2):352-9. PubMed ID: 15998286
[TBL] [Abstract][Full Text] [Related]
30. Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition.
Lin Z; Wang W; Kopajtic T; Revay RS; Uhl GR
Mol Pharmacol; 1999 Aug; 56(2):434-47. PubMed ID: 10419565
[TBL] [Abstract][Full Text] [Related]
31. WIN 35,428 and mazindol are mutually exclusive in binding to the cloned human dopamine transporter.
Xu C; Reith ME
J Pharmacol Exp Ther; 1997 Aug; 282(2):920-7. PubMed ID: 9262359
[TBL] [Abstract][Full Text] [Related]
32. Dopamine transporter tryptophan mutants highlight candidate dopamine- and cocaine-selective domains.
Lin Z; Wang W; Uhl GR
Mol Pharmacol; 2000 Dec; 58(6):1581-92. PubMed ID: 11093799
[TBL] [Abstract][Full Text] [Related]
33. Uptake of a neurotoxin-candidate, (R)-1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline into human dopaminergic neuroblastoma SH-SY5Y cells by dopamine transport system.
Takahashi T; Deng Y; Maruyama W; Dostert P; Kawai M; Naoi M
J Neural Transm Gen Sect; 1994; 98(2):107-18. PubMed ID: 7734108
[TBL] [Abstract][Full Text] [Related]
34. Dopamine transporter mutants selectively enhance MPP+ transport.
Kitayama S; Wang JB; Uhl GR
Synapse; 1993 Sep; 15(1):58-62. PubMed ID: 8310426
[TBL] [Abstract][Full Text] [Related]
35. Isothiocyanate derivatives of cocaine: irreversible inhibition of ligand binding at the dopamine transporter.
Boja JW; Rahman MA; Philip A; Lewin AH; Carroll FI; Kuhar MJ
Mol Pharmacol; 1991 Mar; 39(3):339-45. PubMed ID: 1826041
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding.
Pristupa ZB; Wilson JM; Hoffman BJ; Kish SJ; Niznik HB
Mol Pharmacol; 1994 Jan; 45(1):125-35. PubMed ID: 8302271
[TBL] [Abstract][Full Text] [Related]
37. Drug interactions with the dopamine transporter in cryopreserved human caudate.
Eshleman AJ; Wolfrum K; Mash DC; Christensen K; Janowsky A
J Pharmacol Exp Ther; 2001 Feb; 296(2):442-9. PubMed ID: 11160629
[TBL] [Abstract][Full Text] [Related]
38. Displacement of RTI-55 from the dopamine transporter by cocaine.
Gatley SJ; Volkow ND; Chen R; Fowler JS; Carroll FI; Kuhar MJ
Eur J Pharmacol; 1996 Jan; 296(2):145-51. PubMed ID: 8838450
[TBL] [Abstract][Full Text] [Related]
39. Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism.
Lin Z; Uhl GR
Mol Pharmacol; 2002 Apr; 61(4):885-91. PubMed ID: 11901228
[TBL] [Abstract][Full Text] [Related]
40. Novel in vivo electrophysiological assay for the effects of cocaine and putative "cocaine antagonists" on dopamine transporter activity of substantia nigra and ventral tegmental area dopamine neurons.
Hinerth MA; Collins HA; Baniecki M; Hanson RN; Waszczak BL
Synapse; 2000 Dec; 38(3):305-12. PubMed ID: 11020233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
